Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Thrombosis and Haemostasis

• Publication date

  2006-04-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1160/TH05-08-0569PMID 16676078
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PAI‐1 and vasculopathy: the debate continues

  2004cited by this paper
• siRNAs: applications in functional genomics and potential as therapeutics

  2004cited by this paper
• The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region.

  2004cited by this paper
• Silence of the genes.

  2004cited by this paper
• Rational siRNA design for RNA interference

  2004cited by this paper
• Activation of the interferon system by short-interfering RNAs

  2003cited by this paper
• Enhanced Thrombosis in Atherosclerosis-Prone Mice Is Associated With Increased Arterial Expression of Plasminogen Activator Inhibitor-1

  2003cited by this paper
• Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents

  2003influential reference
• Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing

  2003cited by this paper
• Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease

  2003cited by this paper
• Acute Release of Plasminogen Activator Inhibitor-1 in ST-Segment Elevation Myocardial Infarction Predicts Mortality

  2003cited by this paper
• Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins

  2003cited by this paper
• Cellular uptake and intracellular fate of antisense oligonucleotides.

  2003cited by this paper
• Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.

  2002cited by this paper
• Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy.

  2002cited by this paper
• Lack of Plasminogen Activator Inhibitor-1 Promotes Growth and Abnormal Matrix Remodeling of Advanced Atherosclerotic Plaques in Apolipoprotein E–Deficient Mice

  2002cited by this paper
• Plasminogen activator inhibitor‐1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin

  2001cited by this paper
• Atherosclerosis The Road Ahead

  2001cited by this paper
• Inflammation and thrombosis: the clot thickens.

  2001cited by this paper
• Disruption of the plasminogen activator inhibitor‐1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice

  2001cited by this paper
• Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

  2001cited by this paper
• Plasminogen Activator Inhibitor-1 and Its Cofactor Vitronectin Stabilize Arterial Thrombi After Vascular Injury in Mice

  2001cited by this paper
• Hypertriglyceridemic VLDL downregulates tissue plasminogen activator gene transcription through cis-repressive region(s) in the tissue plasminogen activator promoter in cultured human endothelial cells.

  2000cited by this paper
• The silence of the genes.

  2000cited by this paper
• Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.

  2000cited by this paper
• Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.

  2000cited by this paper
• Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells.

  1999influential reference
• Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells.

  1999cited by this paper
• Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization

  1998cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper
• Phosphorothioate Oligodeoxyribonucleotides Antisense to PAI-1 mRNA Increase Fibrinolysis and Modify Experimental Thrombosis in Rats

  1998cited by this paper
• Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

  1997cited by this paper
• Isolation of Putative Progenitor Endothelial Cells for Angiogenesis

  1997cited by this paper
• Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice.

  1997cited by this paper
• The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.

  1996cited by this paper
• The urokinase receptor is a major vitronectin-binding protein on endothelial cells.

  1996cited by this paper
• Inhibition by modified oligodeoxynucleotides of the expression of type-1 plasminogen activator inhibitor in human endothelial cells.

  1995cited by this paper
• The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.

  1994cited by this paper
• Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells.

  1994cited by this paper
• Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.

  1992cited by this paper
• Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha.

  1989cited by this paper
• cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.

  1986cited by this paper

• The role of visceral peritoneum in LPS mediated inflammatory responses

  2017cites this paper
• HIF-α/MIF and NF-κB/IL-6 axes contribute to the recruitment of CD11b+Gr-1+ myeloid cells in hypoxic microenvironment of HNSCC.

  2014influential citation
• cells modulation by plasminogen activator inhibitor-1 in vascular endothelial Unique secretory dynamics of tissue plasminogen activator and its

  2013cites this paper
• Loss of Arnt (Hif1β) in mouse epidermis triggers dermal angiogenesis, blood vessel dilation and clotting defects

  2012cites this paper
• Targeted transfection increases siRNA uptake and gene silencing of primary endothelial cells in vitro--a quantitative study.

  2010cites this paper
• Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells.

  2009cites this paper
• Adenoviral overexpression and small interfering RNA suppression demonstrate that plasminogen activator inhibitor-1 produces elevated collagen accumulation in normal and keloid fibroblasts.

  2008cites this paper
• Inhibition of plasminogen activator inhibitor‐1 expression by siRNA in rat hepatic stellate cells

  2008cites this paper
• Etude et Développement de Vecteurs Synthétiques pour la Délivrance d'Oligonucléotides à visée thérapeutique.

  2007cites this paper
• Laminin-&agr;4 and Integrin-Linked Kinase Mutations Cause Human Cardiomyopathy Via Simultaneous Defects in Cardiomyocytes and Endothelial Cells

  2007cites this paper
• Laminin- 4 and Integrin-Linked Kinase Mutations Cause Human Cardiomyopathy Via Simultaneous Defects in Cardiomyocytes and Endothelial Cells

  2007cites this paper
• Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells.

  2007cites this paper
• Inhibition of PAI-1 expression in breast cancer carcinoma cells by siRNA at nanomolar range.

  2007cites this paper